Skip to main content
Premium Trial:

Request an Annual Quote

KellBenx Raises $2.5M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Startup biotech firm KellBenx today announced it has raised $2.5 million in an initial funding round.

Four investors participated in the round, three undisclosed venture capital groups and an undisclosed angel investor.

"The funds will be used to launch an [institutional review board]-approved clinical trial and build our Long Island laboratory to analyze the data we are producing," Hassan Bennani, CEO of KellBenx, said in a statement.

Earlier this week, the company announced it had licensed three interleukin biomarkers from Cedars-Sinai Medical Center for the development of tests to predict premature births. The test will be in an ELISA format, but Bennani said that the company is considering next-generation sequencing technologies as well.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.